Organization
University Medical Center Mannheim
5 abstracts
Abstract
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Org: Medical Department, Oncology Therapeutic Development, Charité Universitätsmedizin Berlin, Comprehensive Cancer Center at Ludwig Maximilian University of Munich, MVZ Gesundheitszentrum St. Marien GmbH,
Abstract
INTRAMET: Results of a prospective, single-arm, open-label phase II trial of intraoperative radiotherapy after resection of brain metastases.Org: University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University Hospital, Heidelberg, Germany, University Hospital Bonn, University of Bonn,
Abstract
Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.Org: University Medical Center Mannheim, University of Heidelberg, University Hospital Bonn, University Hospital Leipzig, Heidelberg University Hospital, Heidelberg, Germany,
Abstract
Clinical evidence and benefit of special FDA designations in anti-cancer drugs.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),
Abstract
Association of SARS-CoV-2 vaccinations and personal protective measures with seroconversion and risk of infection in a large real-world cohort of patients with cancer.Org: DKFZ-Hector Cancer Institute and Department of Personalized Oncology, University Medical Center Mannheim, Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), German Center for Lung Research (DZL),